Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Launched by NOVARTIS PHARMACEUTICALS · Jun 6, 2013
Trial Information
Current as of June 10, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of Multiple Sclerosis according to 2010 revised McDonald criteria
- • Disease duration of 10 years or less
- • At least one relapse in the last year
- • EDSS score 0 to 5.0 at entry
- Exclusion Criteria:
- • Active chronic disease of the immune system other than multiple sclerosis
- • History of malignancy within the past 5 years
- • Active systemic bacterial, viral or fungal infections
- • Previous treatment with more than one class of multiple sclerosis therapies except for previous treatment with glatiramer acetate and interferon-beta(s)
- • Any medically unstable condition
- • Unable to undergo MRI scans or repeated blood tests
- • Pregnant or nursing females
- • Women of child-bearing potential must use reliable forms of contraception
- • Other protocol-defined inclusion/exclusion criteria may apply.
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roma, Rm, Italy
Barcelona, Catalunya, Spain
Brugge, , Belgium
Bilbao, Pais Vasco, Spain
Saint Petersburg, , Russian Federation
Atakum / Samsun, , Turkey
Stockholm, , Sweden
Moscow, , Russian Federation
Poznan, , Poland
St Herblain, , France
Lodz, , Poland
Jihlava, , Czech Republic
Osaka City, Osaka, Japan
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials